|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HELZ2 |
Gene summary for HELZ2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HELZ2 | Gene ID | 85441 |
| Gene name | helicase with zinc finger 2 | |
| Gene Alias | PDIP-1 | |
| Cytomap | 20q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000184 | UniProtAcc | Q9BYK8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85441 | HELZ2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.62e-02 | 1.28e-01 | -0.1464 |
| 85441 | HELZ2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.15e-04 | 1.21e-01 | -0.059 |
| 85441 | HELZ2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.19e-08 | 2.33e-01 | 0.096 |
| 85441 | HELZ2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.33e-05 | 1.76e-01 | 0.0338 |
| 85441 | HELZ2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.17e-14 | 5.33e-01 | 0.3859 |
| 85441 | HELZ2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.16e-10 | 7.15e-01 | 0.2585 |
| 85441 | HELZ2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.78e-10 | 3.68e-01 | 0.3005 |
| 85441 | HELZ2 | LZE20T | Human | Esophagus | ESCC | 1.97e-05 | 2.79e-01 | 0.0662 |
| 85441 | HELZ2 | LZE24T | Human | Esophagus | ESCC | 2.92e-15 | 5.29e-01 | 0.0596 |
| 85441 | HELZ2 | LZE21T | Human | Esophagus | ESCC | 2.39e-05 | 3.01e-01 | 0.0655 |
| 85441 | HELZ2 | P1T-E | Human | Esophagus | ESCC | 1.64e-06 | 5.71e-01 | 0.0875 |
| 85441 | HELZ2 | P2T-E | Human | Esophagus | ESCC | 1.63e-10 | 2.58e-01 | 0.1177 |
| 85441 | HELZ2 | P4T-E | Human | Esophagus | ESCC | 1.39e-02 | 1.07e-01 | 0.1323 |
| 85441 | HELZ2 | P5T-E | Human | Esophagus | ESCC | 1.01e-08 | 1.26e-01 | 0.1327 |
| 85441 | HELZ2 | P8T-E | Human | Esophagus | ESCC | 2.35e-03 | 1.06e-01 | 0.0889 |
| 85441 | HELZ2 | P9T-E | Human | Esophagus | ESCC | 2.08e-07 | 2.04e-01 | 0.1131 |
| 85441 | HELZ2 | P10T-E | Human | Esophagus | ESCC | 1.20e-02 | 3.49e-02 | 0.116 |
| 85441 | HELZ2 | P11T-E | Human | Esophagus | ESCC | 1.51e-20 | 6.73e-01 | 0.1426 |
| 85441 | HELZ2 | P12T-E | Human | Esophagus | ESCC | 1.32e-04 | 1.26e-01 | 0.1122 |
| 85441 | HELZ2 | P17T-E | Human | Esophagus | ESCC | 3.65e-08 | 5.79e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0000956 | Colorectum | AD | nuclear-transcribed mRNA catabolic process | 40/3918 | 112/18723 | 2.11e-04 | 2.79e-03 | 40 |
| GO:00064012 | Colorectum | MSS | RNA catabolic process | 102/3467 | 278/18723 | 5.07e-13 | 1.02e-10 | 102 |
| GO:00064022 | Colorectum | MSS | mRNA catabolic process | 89/3467 | 232/18723 | 8.70e-13 | 1.60e-10 | 89 |
| GO:00442702 | Colorectum | MSS | cellular nitrogen compound catabolic process | 141/3467 | 451/18723 | 2.95e-11 | 3.83e-09 | 141 |
| GO:00467002 | Colorectum | MSS | heterocycle catabolic process | 139/3467 | 445/18723 | 4.37e-11 | 5.05e-09 | 139 |
| GO:00346552 | Colorectum | MSS | nucleobase-containing compound catabolic process | 129/3467 | 407/18723 | 7.48e-11 | 8.18e-09 | 129 |
| GO:19013612 | Colorectum | MSS | organic cyclic compound catabolic process | 148/3467 | 495/18723 | 3.47e-10 | 3.18e-08 | 148 |
| GO:00194392 | Colorectum | MSS | aromatic compound catabolic process | 140/3467 | 467/18723 | 8.56e-10 | 6.85e-08 | 140 |
| GO:00009561 | Colorectum | MSS | nuclear-transcribed mRNA catabolic process | 42/3467 | 112/18723 | 1.75e-06 | 5.60e-05 | 42 |
| GO:0000184 | Colorectum | MSS | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 15/3467 | 37/18723 | 1.51e-03 | 1.39e-02 | 15 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HELZ2 | SNV | Missense_Mutation | novel | c.7378N>A | p.Ala2460Thr | p.A2460T | Q9BYK8 | protein_coding | tolerated(0.39) | benign(0.022) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
| HELZ2 | SNV | Missense_Mutation | c.6786G>C | p.Arg2262Ser | p.R2262S | Q9BYK8 | protein_coding | tolerated(0.08) | benign(0.015) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| HELZ2 | SNV | Missense_Mutation | rs369045635 | c.1903C>T | p.Arg635Trp | p.R635W | Q9BYK8 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| HELZ2 | SNV | Missense_Mutation | c.4881N>A | p.Met1627Ile | p.M1627I | Q9BYK8 | protein_coding | tolerated(1) | benign(0.005) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| HELZ2 | SNV | Missense_Mutation | c.568G>C | p.Glu190Gln | p.E190Q | Q9BYK8 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| HELZ2 | SNV | Missense_Mutation | rs151068704 | c.7156N>T | p.Leu2386Phe | p.L2386F | Q9BYK8 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| HELZ2 | SNV | Missense_Mutation | novel | c.3118N>T | p.Ala1040Ser | p.A1040S | Q9BYK8 | protein_coding | tolerated(0.73) | benign(0.239) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| HELZ2 | SNV | Missense_Mutation | novel | c.3116N>T | p.Cys1039Phe | p.C1039F | Q9BYK8 | protein_coding | tolerated(0.18) | benign(0) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| HELZ2 | deletion | Frame_Shift_Del | c.7322delN | p.Lys2441ArgfsTer4 | p.K2441Rfs*4 | Q9BYK8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| HELZ2 | SNV | Missense_Mutation | rs771795577 | c.4556N>A | p.Arg1519His | p.R1519H | Q9BYK8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |